Posted on Jul 08, 2014, 6 a.m.
Epigallocatechin gallate (EGCG) changes the metabolism of pancreatic cancer cells by suppressing the expression of an enzyme associated with cancer.
Lactate dehydrogenase A (LDHA) is an enzyme that is elevated in several human cancers, including pancreatic cancer. Wai-Nang Lee, MD, from the Los Angeles Biomedical Research Institute (LA BioMed; California, USA), and colleagues observe that epigallocatechin gallate (EGCG), the active biologic constituent in green tea, changes the metabolism of pancreatic cancer cells by suppressing LDHA expression. The researchers also found an enzyme inhibitor, oxamate, which is known to reduce LDHA activity, operated in the same manner: It also disrupted the pancreatic cancer cells metabolic system. The study authors submit that: “These results suggest that phytochemical [epigallocatechin gallate] and LDHA inhibitor oxamate confer their anti-cancer activities by disrupting the balance of flux throughout the cellular metabolic network.”
Qing-Yi Lu, Lifeng Zhang, Jennifer K. Yee, Vay-Liang W. Go, Wai-Nang Lee. “Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells.” Metabolomics, May 2014.